<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="publisher-id">MEDI</journal-id>
      <journal-title-group>
        <journal-title>Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0025-7974</issn>
      <issn pub-type="epub">1536-5964</issn>
      <publisher>
        <publisher-name>Wolters Kluwer Health</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26817871</article-id>
      <article-id pub-id-type="pmc">4998245</article-id>
      <article-id pub-id-type="doi">10.1097/MD.0000000000002419</article-id>
      <article-id pub-id-type="art-access-id">02419</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>4300</subject>
        </subj-group>
        <subj-group>
          <subject>Research Article</subject>
          <subject>Clinical Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Extrathyroidal Calcitonin Secreting Tumors: Pancreatic Neuroendocrine Tumors in Patients With Multinodular Goiter</article-title>
        <subtitle>Two Case Reports</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Giannetta</surname>
            <given-names>Elisa</given-names>
          </name>
          <degrees>MD, PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gianfrilli</surname>
            <given-names>Daniele</given-names>
          </name>
          <degrees>MD, PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pozza</surname>
            <given-names>Carlotta</given-names>
          </name>
          <degrees>MD, PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lauretta</surname>
            <given-names>Rosa</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Graziadio</surname>
            <given-names>Chiara</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sbardella</surname>
            <given-names>Emilia</given-names>
          </name>
          <degrees>MD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Baroli</surname>
            <given-names>Alberto</given-names>
          </name>
          <degrees>MD, PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Caronna</surname>
            <given-names>Roberto</given-names>
          </name>
          <degrees>MD, PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chirletti</surname>
            <given-names>Piero</given-names>
          </name>
          <degrees>MD, PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lenzi</surname>
            <given-names>Andrea</given-names>
          </name>
          <degrees>MD, PhD</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Isidori</surname>
            <given-names>Andrea M.</given-names>
          </name>
          <degrees>MD, PhD</degrees>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Liu.</surname>
            <given-names>Yong</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff>From the Department of Experimental Medicine, Sapienza University of Rome, Rome (EG, DG, CP, RL, CG, ES, AL, AMI); Nuclear Medicine Unit, Department of Interventional Oncology, Azienda Ospedaliera-Ospedale di Circolo di Busto Arsizio, Varese (AB); and Department of Surgical Science, Sapienza University of Rome, Rome, Italy (RC, PC).</aff>
      <author-notes>
        <corresp>Correspondence: Andrea M. Isidori, Department of Experimental Medicine, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy (e-mail: <email>andrea.isidori@uniroma1.it).</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>22</day>
        <month>1</month>
        <year>2016</year>
      </pub-date>
      <volume>95</volume>
      <issue>3</issue>
      <elocation-id>e2419</elocation-id>
      <history>
        <date date-type="received">
          <day>14</day>
          <month>9</month>
          <year>2015</year>
        </date>
        <date date-type="rev-recd">
          <day>7</day>
          <month>12</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>9</day>
          <month>12</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2016 Wolters Kluwer Health, Inc. All rights reserved.</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0">
          <license-p>This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be changed in any way or used commercially. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0">http://creativecommons.org/licenses/by-nc-nd/4.0</ext-link></license-p>
        </license>
      </permissions>
      <self-uri xlink:type="simple" xlink:href="medi-95-e2419.pdf"/>
      <abstract>
        <title>Abstract</title>
        <p>Calcitonin is the hallmark of medullary thyroid carcinoma. However, extrathyroidal neuroendocrine tumors can also release calcitonin.</p>
        <p>We report 2 cases of calcitonin-secreting pancreatic tumors found in asymptomatic patients with thyroid nodules referred to our center within 11 months.</p>
        <p>Case 1: A man initially referred for thyroid nodule characterization was found to have hypercalcitoninemia (&gt;200&#x200A;pg/mL) during non-neoplastic fine-needle aspiration.</p>
        <p>Case 2: A woman evaluated for liver metastasis was found to have hypercalcitoninemia and multinodular goiter.</p>
        <p>Our research emphasizes that marked hypercalcitoninemia in the presence of thyroid nodules is not necessarily due to medullary thyroid carcinoma; awareness of this could avoid unnecessary thyroidectomy. The lack of specific symptoms related to hypercalcitoninemia may be the reason that the prevalence of calcitonin-secreting pancreatic tumors is underestimated.</p>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>OPEN-ACCESS</meta-name>
          <meta-value>TRUE</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>High circulating calcitonin levels are associated with medullary thyroid carcinoma.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> However, several other neuroendocrine tumors (NETs) can also release calcitonin, including pheochromocytomas, neuromas and lung, breast, prostate, and colorectal carcinomas.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup> Calcitonin-secreting pancreatic endocrine tumors (CTsPETs) have been described as extremely rare.<sup><xref rid="R4" ref-type="bibr">4</xref></sup> We report 2 consecutive cases of CTsPETs found during the evaluation of patients with hypercalcitoninemia and thyroid nodules. These cases highlight the risk of underestimating calcitonin as a tumor marker for pancreatic NET.</p>
    </sec>
    <sec>
      <title>CASE REPORTS</title>
      <p>Written informed consent was obtained from both patients for the publication of this manuscript and accompanying images.</p>
      <sec sec-type="cases">
        <title>Case 1</title>
        <p>A 53-year-old Caucasian man was referred to our department for an elevated serum calcitonin level (253&#x200A;pg/mL, reference range 0&#x2013;10) discovered during an evaluation of thyroid nodules. The patient was asymptomatic and was not taking any medication; his family history included only lung cancer, in his father. Blood testing showed polycythemia vera, for which he underwent periodic blood tests. TSH, FT3, and FT4 were normal and thyroid antibodies negative. Color Doppler ultrasound (CDUS) revealed 2 non-homogeneous thyroid nodules of 0.6 and 1.8&#x200A;cm, with a medium elastography pattern (3B and 2 respectively). Fine needle aspiration cytology (FNAC) suggested benign hyperplastic nodules (Thy 2, British Thyroid Association, BTA-RCP 2007); calcitonin measurement in fine needle wash-out of both thyroid nodules was negative (1.24 and 1.68&#x200A;pg/mL respectively). Serum electrolytes, PTHi, 24-h urinary metanephrines (144&#x200A;mcg/24&#x200A;h&#x200A;&lt;&#x200A;345) and vanillylmandelic acid (VMA&#x200A;=&#x200A;8.0&#x200A;mg/24&#x200A;h &lt;13.6) were normal.</p>
        <p>Hypercalcitoninemia was confirmed in 2 further samples (388 and 443&#x200A;pg/mL). We started an extensive search for extrathyroidal causes of hypercalcitoninemia. NET markers were normal: neuron-specific enolase (NSE) (5&#x200A;ng/mL &lt;10), gastrin (50&#x200A;pg/mL &lt;120), chromogranin A-CgA (44&#x200A;ng/mL &lt;90), CEA (1.5&#x200A;ng/mL &lt;5), VIP (12&#x200A;pmol/L &lt;30), 5HT+5HTP (4.0&#x200A;mg/24&#x200A;h &lt;5), PSA (0.65&#x200A;ng/mL &lt;2.3), and 24-h urinary 5HIAA (3.0&#x200A;mg/24&#x200A;h &lt;6). Gastroscopy and prostate US were negative. Abdominal computed tomography showed a pancreatic nodule (1.8&#x200A;cm) with moderate enhancement during arterial phase, confirmed on magnetic resonance imaging (Figure <xref ref-type="fig" rid="F1">1</xref>A) as suggestive of NET. An integrated nuclear medicine approach was undertaken (A.B.): <sup>18</sup>F-DOPA PET/CT (Figure <xref ref-type="fig" rid="F1">1</xref>B - lower panel) revealed mild pancreatic metabolization while <sup>18</sup>F-FDG PET/CT (Figure <xref ref-type="fig" rid="F1">1</xref>B - upper panel) and OctreoScan +SPECT/CT were negative.</p>
        <fig id="F1" position="float">
          <label>FIGURE 1</label>
          <caption>
            <p>MRI, <sup>18</sup>F-FDG PET/CT imaging, and immunostaining for calcitonin in Case 1. A, MRI scan shows a solid 18-mm lesion in the pancreatic tail (arrows), which appears hypointense on T1 and slightly hyperintense on T2. Contrast-enhanced sequences show hypervascularity in arterial phase with persistent enhancement in the subsequent phases. B, <sup>18</sup>F-FDG PET/CT (in the upper part of the panel) and <sup>18</sup>F-DOPA PET/TC (in the lower part of the panel) both show no significant metabolic activity in the pancreatic lesion. C, Immunostaining of the pancreatic nodule shows intense calcitonin staining (brown). MRI&#x200A;=&#x200A;magnetic resonance imaging.</p>
          </caption>
          <graphic xlink:href="medi-95-e2419-g001"/>
        </fig>
        <p>The patient underwent a distal pancreatectomy (P.C.) that confirmed a well-differentiated NET (2.3&#x200A;cm, G1, proliferation index 2%) which was positive for calcitonin, NCAM, CgA, synaptophysin, NSE immunostaining (Figure <xref ref-type="fig" rid="F1">1</xref>C) and negative for insulin, glucagon, gastrin, somatostatin, and serotonin.</p>
        <p>Calcitonin gradually normalized after surgery (Figure <xref ref-type="fig" rid="F2">2</xref>); prolonged follow-up (24 months) showed repeatedly normal calcitonin levels, confirming disease eradication. Genetic testing for MEN1 (exons 2,3,4,5,6,7,8,9,10) and RET (exons 10,11,13,14,15,16) mutations associated with CTsPETs were negative.</p>
        <fig id="F2" position="float">
          <label>FIGURE 2</label>
          <caption>
            <p>Time course of postsurgical calcitonin normalization (solid: Case 1; open: Case 2).</p>
          </caption>
          <graphic xlink:href="medi-95-e2419-g002"/>
        </fig>
      </sec>
      <sec sec-type="cases">
        <title>Case 2</title>
        <p>A 78-year-old Caucasian woman with a 5-month history of vague abdominal discomfort and constipation complained of a recent onset gastric pain and underwent a liver US, which found 2 suspect non-homogeneous lesions (1.6 and 0.6&#x200A;cm) in liver segment VII. The patient had known thyroid nodules and was referred for endocrine evaluation. Her brother had died from hepatic metastases from a tumor of unknown origin. The patient was not taking any medications. Before admission she had an abdominal computed tomography scan, which revealed a nodule (4.0&#x200A;cm) in the pancreatic tail, and a <sup>18</sup>F-FDG PET/CT scan, that was negative. NET marker screening showed: hypercalcitoninemia (126&#x200A;pg/mL: <italic>n.v.</italic> 0&#x2013;10), confirmed in 2 subsequent measurements (122 and 218&#x200A;pg/mL), with normal NSE (4&#x200A;ng/mL &lt;10), gastrin (64&#x200A;pg/mL &lt;120), CgA (75&#x200A;ng/mL &lt;90), CEA (1.79&#x200A;ng/mL &lt;5), VIP (20&#x200A;pmol/L &lt;30), 5HT+5HTP (4.0&#x200A;mg/24&#x200A;h &lt;5), and 24-h urinary 5HIAA (4.0&#x200A;mg/24&#x200A;h &lt;6). Thyroid hormones and antibodies were normal. Thyroid CDUS confirmed 2 hypoechoic nodules (1.2 and 1.7&#x200A;cm) with a medium (3A) elastography pattern. FNAC showed benign hyperplastic nodules (Thy 2) with unremarkable calcitonin levels in needle wash-out. Serum electrolytes, PTHi, and 24-h urinary metanephrines (53.0&#x200A;mcg/24&#x200A;h) and VMA (6.0&#x200A;mg/24&#x200A;h) were normal.</p>
        <p>The patient underwent US-guided biopsy of the hepatic lesion that was consistent with metastasis from a well-differentiated NET (panCKAE1/AE3+, CK8/18+, CK7-, CK20-, Synaptophysin+, NSE+/-, CgA-/+, HepPar1-, alfaFP-, TTF1-, CDX2-, Calcitonin-; Ki67 staining &lt;3%). The patient underwent a distal pancreatectomy and liver metastasectomy (P.C.). Histopathology revealed a well-differentiated 5.0-cm pancreatic NET with angioinvasion (G1, proliferation index 2%), with immunostaining positive for calcitonin, NCAM, CgA, synaptophysin and NSE and negative for glucagon, gastrin, insulin, somatostatin, and serotonin. Calcitonin levels normalized rapidly post-surgery (+24 h&#x200A;=&#x200A;101&#x200A;pg/mL; +48 h&#x200A;=&#x200A;3.62&#x200A;pg/mL; +21 days&#x200A;=&#x200A;1.31&#x200A;pg/mL) (Figure <xref ref-type="fig" rid="F2">2</xref>). Genetic testing was negative.</p>
        <p>The patient is currently doing well and is followed up regularly in the outpatient clinic.</p>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>The discovery of 2 cases of CTsPETs within 11 months in our center suggests that extrathyroid calcitonin secretion by NET could be more common than generally thought.<sup><xref rid="R5" ref-type="bibr">5</xref>&#x2013;<xref rid="R8" ref-type="bibr">8</xref></sup> The absence of specific symptoms (except for a vague abdominal discomfort) is problematic for both identification of the source and post-operative monitoring.</p>
      <p>Several extrathyroidal tumors can produce ectopic calcitonin, including pheochromocytomas, pancreatic NETs, adrenocortical carcinomas, NETs of esophagus, acute leukemia, lung cancers, cervical tumors, prostatic carcinomas, breast cancers, renal carcinomas, gastrointestinal tract tumors.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> In all these tumors, the anatomic localization, rapid growth, and frequent cosecretion of other hormones (including ACTH, gastrin, catecholamines, and somatostatin) drive the clinical presentation and allow rapid localization of the source.<sup><xref rid="R9" ref-type="bibr">9</xref>&#x2013;<xref rid="R11" ref-type="bibr">11</xref></sup></p>
      <p>Symptoms of pancreatic NET can include diarrhea, which has been associated with cosecretion of somatostatin<sup><xref rid="R8" ref-type="bibr">8</xref></sup> or the histological nature of the tumor.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> However, neither of our patients complained of diarrhea.</p>
      <p>In contrast, isolated ectopic calcitonin secretion has not been associated with a specific clinical picture and can remain silent, meaning patients are unlikely to seek medical help.</p>
      <p>The lack of emphasis on differential diagnosis leads to general unawareness of CTsPETs and some cases probably remain undiagnosed.</p>
      <p>Case 1 suggests that elevated calcitonin levels should be investigated with care even in the presence of thyroid nodules, and especially when the nodules have few suspicious features; the pancreas should be screened first. In fact, if not promptly diagnosed, CTsPETs can metastasize, as in Case 2.</p>
      <p>Calcitonin measurement should be included in the work-up of any neuroendocrine pancreatic lesion, with or without metastases, even if metastases can lose secretory activity, probably as they dedifferentiate (Case 2).<sup><xref rid="R6" ref-type="bibr">6</xref></sup> Calcitonin has proved sensitive in various paraneoplastic syndromes.<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref></sup></p>
      <p>Herein, we showed 2 cases with positive immunostaining for calcitonin in PETs in which serum calcitonin decay (24&#x200A;h, 48&#x200A;h, and 21 days) was helpful in postsurgical surveillance. Nuclear medicine imaging supported the diagnosis and the combined morphological/functional imaging provided by hybrid PET/CT scan offered the best guide for surgery.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> In both cases, the absence of glucose metabolism in the pancreatic lesions supported the diagnosis of biologically nonaggressive CTsPETs.</p>
      <p>In Case 1, the lack of F-DOPA fixation in the thyroid strengthened the suspicion of an extrathyroid calcitonin secretion, already suggested by the negative calcitonin measurement in FNAC needle wash.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> Of note was that the pancreatic nodule failed to metabolize F-DOPA consistently, with low aromatic amino acid decarboxylase activity (false negative). Octreoscan was negative, suggesting low or negative SSTR-2 expression; unfortunately the more sensitive <sup>68</sup>Gallium-DOTATOC-PET scan was not performed.<sup><xref rid="R11" ref-type="bibr">11</xref></sup></p>
      <p>The negative genetic tests suggest the sporadic nature of these pancreatic lesions.</p>
      <p>In conclusion, when calcitonin levels are elevated and thyroid examination is not clearly suggestive of medullary thyroid carcinoma or C-cell hyperplasia, general screening of extrathyroidal calcitonin secretion is recommended. CTsPET should be suspected in the differential diagnosis, especially in view of the lack of specific symptoms, that may further delay diagnosis. Routine serum calcitonin measurement may be a highly sensitive adjunct to identify a subset of CTsNETs, and calcitonin monitoring may enable early detection and postoperative surveillance.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgment</title>
      <p>The authors would like to thank Marie-H&#xE9;l&#xE8;ne Hayles for revision of the English text.</p>
    </ack>
    <fn-group>
      <fn fn-type="abbr">
        <p>Abbreviations: CDUS = color doppler ultrasound, CgA = chromogranin A, CTsPET = calcitonin-secreting pancreatic tumors, FNAC = fine needle aspiration cytology, MTC = medullary thyroid carcinoma, NETs = neuroendocrine tumors, NSE = neuron-specific enolase, VMA = vanillylmandelic acid.</p>
      </fn>
      <fn fn-type="COI-statement">
        <p>The authors have no conflicts of interest to disclose.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="R1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>K</given-names></name><name><surname>Roman</surname><given-names>SA</given-names></name><name><surname>Wang</surname><given-names>TS</given-names></name><etal/></person-group>
<article-title>Calcitonin measurement in evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis</article-title>. <source><italic>J Clin Endocrinol Metab</italic></source>
<year>2008</year>; <volume>93</volume>:<fpage>2173</fpage>&#x2013;<lpage>2180</lpage>.<pub-id pub-id-type="pmid">18364376</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cvijovic</surname><given-names>G</given-names></name><name><surname>Micic</surname><given-names>D</given-names></name><name><surname>Kendereski</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Ectopic calcitonin secretion in a woman with large cell neuroendocrine lung carcinoma</article-title>. <source><italic>Hormones (Athens)</italic></source>
<year>2013</year>; <volume>12</volume>:<fpage>584</fpage>&#x2013;<lpage>590</lpage>.<pub-id pub-id-type="pmid">24457407</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>KE</given-names></name><name><surname>Wolfsen</surname><given-names>AR</given-names></name><name><surname>Forster</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Calcitonin in nonthyroidal cancer</article-title>. <source><italic>J Clin Endocrinol Metab</italic></source>
<year>1979</year>; <volume>49</volume>:<fpage>438</fpage>&#x2013;<lpage>444</lpage>.<pub-id pub-id-type="pmid">468977</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>R</given-names></name><name><surname>Waldmann</surname><given-names>J</given-names></name><name><surname>Swaid</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>Calcitonin-secreting pancreatic endocrine tumors: systematic analysis of a rare tumor entity</article-title>. <source><italic>Pancreas</italic></source>
<year>2011</year>; <volume>40</volume>:<fpage>213</fpage>&#x2013;<lpage>221</lpage>.<pub-id pub-id-type="pmid">21178652</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksson</surname><given-names>B</given-names></name><name><surname>Arnberg</surname><given-names>H</given-names></name><name><surname>Lindgren</surname><given-names>PG</given-names></name><etal/></person-group>
<article-title>Neuroendocrine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients</article-title>. <source><italic>J Intern Med</italic></source>
<year>1990</year>; <volume>228</volume>:<fpage>103</fpage>&#x2013;<lpage>113</lpage>.<pub-id pub-id-type="pmid">2168468</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>RT</given-names></name><name><surname>Cadiot</surname><given-names>G</given-names></name><name><surname>Brandi</surname><given-names>ML</given-names></name><etal/></person-group>
<article-title>ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes</article-title>. <source><italic>Neuroendocrinology</italic></source>
<year>2012</year>; <volume>95</volume>:<fpage>98</fpage>&#x2013;<lpage>119</lpage>.<pub-id pub-id-type="pmid">22261919</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kov&#xE1;&#x10D;ov&#xE1;</surname><given-names>M</given-names></name><name><surname>Filkov&#xE1;</surname><given-names>M</given-names></name><name><surname>Poto&#x10D;&#xE1;rov&#xE1;</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Calcitonin-secreting pancreatic neuroendocrine tumors: a case report and review of the literature</article-title>. <source><italic>Endocr Pract</italic></source>
<year>2014</year>; <volume>20</volume>:<fpage>e140</fpage>&#x2013;<lpage>e144</lpage>.<pub-id pub-id-type="pmid">24793921</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Do Cao</surname><given-names>C</given-names></name><name><surname>Mekinian</surname><given-names>A</given-names></name><name><surname>Ladsous</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Hypercalcitonemia revealing a somatostatinoma</article-title>. <source><italic>Ann Endocrinol (Paris)</italic></source>
<year>2010</year>; <volume>71</volume>:<fpage>553</fpage>&#x2013;<lpage>557</lpage>.<pub-id pub-id-type="pmid">20817146</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asa</surname><given-names>SL</given-names></name><name><surname>Kovacs</surname><given-names>K</given-names></name><name><surname>Killinger</surname><given-names>DW</given-names></name><etal/></person-group>
<article-title>Pancreatic islet cell carcinoma producing gastrin, ACTH, alpha-endorphin, somatostatin and calcitonin</article-title>. <source><italic>Am J Gastroenterol</italic></source>
<year>1980</year>; <volume>74</volume>:<fpage>30</fpage>&#x2013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">6107042</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamberts</surname><given-names>SW</given-names></name><name><surname>Hackeng</surname><given-names>WH</given-names></name><name><surname>Visser</surname><given-names>TJ</given-names></name></person-group>
<article-title>Dissociation and association between calcitonin and adrenocorticotropin secretion</article-title>. <source><italic>J Clin Endocrinol Metab</italic></source>
<year>1980</year>; <volume>50</volume>:<fpage>565</fpage>&#x2013;<lpage>568</lpage>.<pub-id pub-id-type="pmid">6244325</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isidori</surname><given-names>AM</given-names></name><name><surname>Sbardella</surname><given-names>E</given-names></name><name><surname>Zatelli</surname><given-names>MC</given-names></name><etal/></person-group>
<article-title>Conventional and nuclear medicine imaging in ectopic Cushing's syndrome: a systemic review</article-title>. <source><italic>J Clin Endocrinol Metab</italic></source>
<year>2015</year>; <volume>100</volume>:<fpage>3231</fpage>&#x2013;<lpage>3244</lpage>.<pub-id pub-id-type="pmid">26158607</pub-id></mixed-citation>
      </ref>
      <ref id="R12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isidori</surname><given-names>AM</given-names></name><name><surname>Kaltsas</surname><given-names>GA</given-names></name><name><surname>Pozza</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up</article-title>. <source><italic>J Clin Endocrinol Metab</italic></source>
<year>2006</year>; <volume>91</volume>:<fpage>371</fpage>&#x2013;<lpage>377</lpage>.<pub-id pub-id-type="pmid">16303835</pub-id></mixed-citation>
      </ref>
      <ref id="R13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dudczak</surname><given-names>R</given-names></name></person-group>
<article-title>Traub-Weidinger T: PET and PET/CT in endocrine tumours</article-title>. <source><italic>Eur J Radiol</italic></source>
<year>2010</year>; <volume>73</volume>:<fpage>481</fpage>&#x2013;<lpage>493</lpage>.<pub-id pub-id-type="pmid">20089377</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boi</surname><given-names>F</given-names></name><name><surname>Maurelli</surname><given-names>I</given-names></name><name><surname>Pinna</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma</article-title>. <source><italic>J Clin Endocrinol Metab</italic></source>
<year>2007</year>; <volume>92</volume>:<fpage>2115</fpage>&#x2013;<lpage>2118</lpage>.<pub-id pub-id-type="pmid">17405835</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
